GILD · Earnings call · 2026Q3T · Full report

Gamgertamig Clinical Progress

GILEAD SCIENCES, INC. · 2026-10-29 · Importance 31 · Surprise 42

Management said it expects to present additional gamgertamig data later this year, particularly in autoimmune cytopenia and immune thrombocytopenia. It characterized B-cell depletion as a broader opportunity across multiple diseases. Gilead reaffirmed its commitment to begin a Phase 3 study in autoimmune cytopenia next year.

Key facts

• Gilead expected to present additional Phase 1 gamgertamig data in immune thrombocytopenia at a medical congress later in 2026.
• Gilead plans to present more gamgertamig data at a conference later in 2026, including data in autoimmune cytopenia and immune thrombocytopenia.
• Gilead remains committed to bringing gamgertamig into a Phase 3 study in autoimmune cytopenia next year.